SIMCERE PHARMA 02096
SIMCERE PHARMA (02096) Company Profile
| Code | 02096 |
|---|---|
| Name (EN) | SIMCERE PHARMA |
| Board | Main Board |
| ISIN | HK0000658531 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025-06 | 2025 | 2026-06 |
|---|---|---|---|---|---|---|---|
| Revenue | 5B | 6.32B | 6.61B | 6.64B | 3.58B | 7.73B | 4.58B |
| Cost of sales | -691.06M | -765.11M | |||||
| Gross profit | 3.92B | 5B | 4.98B | 5.32B | 2.89B | 6.31B | 3.82B |
| Other income and gains, net | 149.51M | 172.81M | 166.22M | 250.84M | 68.22M | 181.13M | 85.89M |
| Selling and distribution expenses | -2.04B | -2.4B | -2.36B | -2.51B | -1.35B | -2.91B | -1.71B |
| Administrative expenses | -366.66M | -446.08M | -499.28M | -529.69M | -265.64M | -599.3M | -321.98M |
| Operating profit | 1.45B | 860.61M | 711.8M | 836.49M | 682.06M | 1.56B | 970.11M |
| Net finance costs | -2.56M | -34.41M | -34.57M | -30.79M | -21.95M | -21.26M | -832K |
| Share of associates and JVs | -44.19M | 190K | 7.84M | 2.16M | -1.91M | -1.11M | -1.28M |
| Profit before tax | 1.4B | 886.25M | 740.04M | 808.72M | 659.93M | 1.51B | 966.72M |
| Income tax expense | -97.12M | -40.48M | -26.09M | -86.71M | -58.88M | -170.32M | -140.18M |
| Profit for the year | 1.5B | 926.73M | 713.95M | 722M | 601.05M | 1.34B | 826.54M |
| Profit attributable to owners | 1.51B | 930.87M | 714.76M | 722M | 601.05M | 1.34B | 828.72M |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026-06 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 973.14M | 1.66B | 2.01B | 1.95B | 3.51B | 3.07B |
| Trade and bills receivables | 2.4B | 2.34B | 2.63B | 2.7B | 2.84B | 2.4B |
| Inventories | 235.16M | 304.78M | 614.56M | 593.77M | 589.5M | 632.91M |
| Total current assets | 4.98B | 5.46B | 5.64B | 5.49B | 7.39B | 7.47B |
| Total assets | 10.16B | 10.79B | 10.85B | 11.6B | 14.73B | 13.86B |
| Total current liabilities | 3.06B | 2.97B | 2.69B | 2.73B | 3.35B | 3.93B |
| Total liabilities | 3.7B | 3.64B | 3.63B | 4.47B | 5.31B | 5.97B |
| Total equity | 6.46B | 7.15B | 7.22B | 7.13B | 9.41B | 9.49B |
| Equity attributable to owners | 6.44B | 7.13B | 7.22B | 7.13B | 9.41B | 9.42B |
| Item | 2021 | 2022 | 2023 | 2024 | 2025-06 | 2025 | 2026-06 |
|---|---|---|---|---|---|---|---|
| Net cash from operating activities | -201.97M | 1.35B | 151.05M | 1.39B | 863M | 2.01B | 1.6B |
| Net cash from investing activities | -435.5M | 68.31M | 1.09B | -1.07B | -1.33B | ||
| Net cash from financing activities | -1.62B | -753.68M | -894.83M | -376.56M | 894.39M | ||
| Net increase in cash | -2.26B | 668.72M | 344.02M | -58.13M | 1.58B |
| Date | Type | Ratio | Price | Amount | Summary |
|---|---|---|---|---|---|
| 2026-08-21 | Share Scheme | 0 HKD | 先聲藥業於2026年8月21日根據2021年受限制股份單位計劃按零代價向8名合資格參與者授出合共795,000份受限制股份單位（相當於795,000股相關股份），股份收市價為每股12.08港元。 |
This page shows SIMCERE PHARMA (02096) company profile, historical financial statements and board of directors. Financial data comes from public financial disclosures in HKEX display documents, grouped by reporting period; the director roster comes from HKEXnews.
Site Nature: This website (cibo.hk) is an independent technology product showcase platform established by Panda Securities Limited (“the Company”), dedicated to demonstrating the data analysis capabilities of AI technology products and facilitating research exchange. This website itself and all data analysis content displayed herein do not constitute, and are not involved in, any regulated activity or licensed service requiring approval by the Hong Kong Securities and Futures Commission (“SFC”) under the Securities and Futures Ordinance. Browsing or using the content of this website does not establish any regulated client relationship with the Company.
Not Investment Advice: Any information contained on this website (including but not limited to data analysis charts, statistical results, allotment rate comparisons, etc.) is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, guarantee, or endorsement of any investment product or strategy. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should understand that all investment decisions involve risk. Users should make investment decisions based on their own independent judgment, financial situation, investment objectives, and risk tolerance, and consult independent licensed financial advisors or professional advice when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions or actions made by users based on the information on this website.
Technical Limitations: This AI analysis tool is algorithm-driven and data-based. Its analysis results are limited by model capability, data quality, market conditions, and other factors. Past analysis results are not reliable indicators of future performance. The Company does not guarantee the accuracy, completeness, timeliness, or suitability of the analysis results of this tool. All analysis results are automatically generated by AI algorithms, and have not been manually reviewed or verified by the publisher. Analysis charts, statistical data, and trend assessments may contain errors or biases.
Data Sources: The data on this page is sourced from publicly disclosed documents published by HKEX News and other institutions. The relevant institutions make no warranty regarding the accuracy, timeliness, or completeness of such data, nor do they endorse the analysis conclusions derived from such data.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated securities and futures trading services, investment advisory, and other licensed activities provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong Securities and Futures Commission (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). The publisher of this website shall not be liable for any direct or indirect losses arising from the use of this website or its analysis results. Use of this website constitutes acceptance of this disclaimer.
